Table 2.
Primary outcome using Barthel index at 6 months
| Aspirin | LMWH | Unadjusted OR (95% CI) | Adjusted OR*(95% CI) | |
|---|---|---|---|---|
| All treated patients | ||||
| Good outcome | 213 (73%) | 226 (75%) | 1·10 (0·77–1·59) | 1·18 (0·79–1·75)† |
| Bad outcome | 80 (27%) | 77 (25%) | ||
| LAOD patients | ||||
| Good outcome | 119 (69%) | 131 (73%) | 1·19 (0·75–1·89) | 1·21 (0·74–1·99) |
| Bad outcome | 53 (31%) | 49 (27%) | ||
| Non-LAOD patients | ||||
| Good outcome | 93 (78%) | 95 (79%) | 1·02 (0·55–1·89) | 1·21 (0·61–2·39) |
| Bad outcome | 26 (22%) | 26 (21%) | ||
Good outcome is defined as survival with Barthel index ≥85; bad outcome is defined as died or Barthel index ≤80.
*
Odds ratio (OR) after adjustment for the stratification variables: time from onset of stroke (0–24 h, 24–48 h), National Institutes of Health stroke scale score at baseline (0–8, ≥9), and neurovascular investigations at randomisation (vascular lesion present, vascular lesion status unknown). OR >1 indicate advantage of low-molecular-weight heparin (LMWH).
†
OR after adjustment for large artery occlusive disease (LAOD) status in addition to the three stratification variables.